Skip to content
value.today

Neurogene Inc.

NGNE
$30 Mlast known market cap, Jul 2023 — no current value
Compare
World rank
—
no current market cap
Revenue
$0 M
For year ending December-2025
value.today research
Net income
$-33 M
value.today research
Employees
131
As of March 16, 2026
value.today research

Neurogene Inc. in brief

Neurogene Inc. is a listed company in the Pharmaceutical industry, based in Washington, USA. It was founded in 2003. Its last known market value was $30 M (July 2023); there is no current figure. In the year to December 2025 it had sales of $0 M and a net loss of $33 M. It employs about 131 people. Its shares trade under the symbol NGNE (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Neurogene Inc.

Neoleukin Therapeutics is a Advanced Computational method to build entirely new de novo therapeutic proteins to treat serious immunological disorders including cancer and autoimmunity company. The headquarters is in USA.

Neurogene Inc. timeline

7 events, 2003–2023
  1. 2003
  2. 🏁
    · approximate
    Founded
  3. 2007
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2013
  6. ✎
    Renamed Aquinox Pharmaceuticals, Inc
    Formerly Aquinox Pharmaceuticals (Usa) Inc.
  7. 2014
  8. 🔔
    · approximate
    Initial public offering on Nasdaq
  9. 🔔
    Initial public offering as Aquinox Pharmaceuticals, Inc
    Final prospectus filed with the SEC on 7 March 2014; shares registered for exchange trading on 3 March 2014.
  10. 2019
  11. ✎
    Renamed Neoleukin Therapeutics, Inc.
    Formerly Aquinox Pharmaceuticals, Inc.
  12. 2023
  13. ✎
    Renamed Neurogene Inc.
    Formerly Neoleukin Therapeutics, Inc..

Events of Neurogene Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$160 M$319 M$479 M$638 M2020202120222023

World rank over time

▼ down 17,311 places since 2020
2020-01-01: #10453#10,45320202021-01-01: #10364#10,36420212022-01-07: #19798#19,79820222022-12-25: #29786#29,78620222023-07-30: #27764#27,7642023

Rank in USA: #2,392 (Jan 2020) · #2,618 (Jan 2021) · #3,963 (Jan 2022) · #5,334 (Dec 2022) · #5,009 (Jul 2023)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
-12.5%
Liabilities / assets
8.2%
Revenue growth
-96.3%
R&D / revenue
6621.7%
Revenue per employee
$0 K
Profit per employee
$-253 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $25M, net income $-32M$25MFY18Fiscal year ending Dec 2019: revenue —, net income $-69M—FY19Fiscal year ending Dec 2020: revenue —, net income $-33M—FY20Fiscal year ending Dec 2021: revenue —, net income $-61M—FY21Fiscal year ending Dec 2022: revenue —, net income $-55M—FY22Fiscal year ending Dec 2023: revenue —, net income $-36M—FY23Fiscal year ending Dec 2024: revenue $1M, net income $-75M$1MFY24Fiscal year ending Dec 2025: revenue —, net income $-90M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-103M$-90M—
Dec 2024$1M—$-83M$-75M-8167.4%
Dec 2023——$-56M$-36M—
Dec 2022——$-57M$-55M—
Dec 2021——$-61M$-61M—
Dec 2020——$-34M$-33M—
Dec 2019——$-71M$-69M—
Dec 2018$25M—$-33M$-32M-126.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-77M$1M$-78M$-4.24—
Dec 2024$-71M$1M$-71M$-4.28—
Dec 2023$-51M$0M$-52M——
Dec 2022$-53M$2M$-55M$-1.04—
Dec 2021$-48M$3M$-51M$-1.10—
Dec 2020$-25M$2M$-27M$-0.64—
Dec 2019$-15M$1M$-16M$-2.57—
Dec 2018$-32M$0M$-32M$-1.34—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-20M—Dec ’24Three months to Mar 2025: revenue —, net income $-23M—Mar ’25Three months to Jun 2025: revenue —, net income $-22M—Jun ’25Three months to Sep 2025: revenue —, net income $-21M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-25M—Dec ’25Three months to Mar 2026: revenue —, net income $-31M—Mar ’26Three months to Jun 2026: revenue —, net income $-34M—Jun ’26Three months to Sep 2026: revenue —, net income $-29M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-29M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Neurogene Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-103 M
Net income
$-33 M

For year ending December-2025

Balance sheet

Total assets
$289 M
Total liabilities
$24 M
Total equity
$265 M

As of December-2025

Top 100 institutional investors in Neurogene Inc.#

As of Sep 30, 2026
132 institutions held 24.0 M shares (more than all shares outstanding: lent and sub-advised shares are reported by more than one filer) on Sep 30, 2026. The ten largest hold 69.1%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Neurogene Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Jennison Associates LLC2,229,082+1,710,500 (+329.84%)10.77%$62 MNov 16, 2026
2Samsara Biocapital, LLC1,867,127+150,000 (+8.74%)9.02%$52 MNov 16, 2026
3Casdin Capital, LLC1,585,361+40,000 (+2.59%)7.66%$44 MNov 16, 2026
4Redmile Group, LLC1,562,199+150,000 (+10.62%)7.55%$43 MNov 16, 2026
5RTW Investments, LP1,512,456+150,000 (+11.01%)7.31%$42 MNov 16, 2026
6BlackRock, Inc.1,471,936+413,953 (+39.13%)7.11%$41 MNov 13, 2026
7EcoR1 Capital, LLC1,271,3420 (0.00%)6.14%$35 MNov 16, 2026
8Baker Bros. Advisors LP991,6910 (0.00%)4.79%$28 MNov 16, 2026
9Trails Edge Capital Partners, LP964,885+250,000 (+34.97%)4.66%$27 MNov 16, 2026
10T. Rowe Price Investment Management, Inc.850,123New4.11%$24 MNov 16, 2026
11MPM Bioimpact LLC771,839New3.73%$21 MNov 16, 2026
12Vanguard Capital Management LLC711,290+174,765 (+32.57%)3.44%$20 MNov 13, 2026
13Toronto Dominion Bank681,3370 (0.00%)3.29%$19 MNov 16, 2026
14Franklin Templeton Inc630,859+426,579 (+208.82%)3.05%$18 MNov 12, 2026
15State Street Corp549,269+324,947 (+144.86%)2.65%$15 MNov 12, 2026
16UBS Group AG417,651+246,362 (+143.83%)2.02%$12 MNov 10, 2026
17Geode Capital Management, LLC412,768+119,586 (+40.79%)1.99%$11 MNov 6, 2026
18FMR LLC383,249+87,688 (+29.67%)1.85%$11 MNov 10, 2026
19ArrowMark Colorado Holdings LLC378,829+36,376 (+10.62%)1.83%$11 MNov 16, 2026
20Tyro Capital Management LLC304,401New1.47%$8 MNov 12, 2026
21Balyasny Asset Management L.P.303,994-514,712 (-62.87%)1.47%$8 MNov 16, 2026
22Great Point Partners LLC300,000-52,180 (-14.82%)1.45%$8 MNov 16, 2026
23Point72 Asset Management, L.P.238,967+97,047 (+68.38%)1.15%$7 MNov 16, 2026
24Morgan Stanley221,090+29,366 (+15.32%)1.07%$6 MNov 13, 2026
25Driehaus Capital Management LLC218,528+75,000 (+52.25%)1.06%$6 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Neurogene Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Jones Hill Capital LP217,700New1.05%$6 MNov 13, 2026
27Integral Health Asset Management, LLC200,000New0.97%$6 MNov 16, 2026
28Moore Capital Management, LP181,479+39,843 (+28.13%)0.88%$5 MNov 16, 2026
29Vanguard Portfolio Management LLC174,262+78,661 (+82.28%)0.84%$5 MNov 13, 2026
30Marshall Wace, LLP168,509New0.81%$5 MNov 13, 2026
31Rock Springs Capital Management LP154,401+47,651 (+44.64%)0.75%$4 MNov 16, 2026
32DAFNA Capital Management LLC150,532+61,500 (+69.08%)0.73%$4 MNov 16, 2026
33Northern Trust Corp133,034+29,393 (+28.36%)0.64%$4 MNov 16, 2026
34Goldman Sachs Group Inc121,193+19,917 (+19.67%)0.59%$3 MNov 16, 2026
35Vestal Point Capital, LP115,000New0.56%$3 MNov 16, 2026
36Deutsche Bank AG\107,949+1,289 (+1.21%)0.52%$3 MNov 6, 2026
37Vanguard Fiduciary Trust Co104,643+30,381 (+40.91%)0.51%$3 MNov 13, 2026
38Citadel Advisors LLC92,858-316,124 (-77.30%)0.45%$3 MNov 16, 2026
39Dimensional Fund Advisors LP87,700+55,072 (+168.79%)0.42%$2 MNov 4, 2026
40Woodline Partners LP83,8350 (0.00%)0.41%$2 MNov 16, 2026
41Blair William & Co/il79,081-67,824 (-46.17%)0.38%$2 MNov 10, 2026
42Jpmorgan Chase & Co61,953+71 (+0.11%)0.30%$2 MNov 12, 2026
43Burkehill Global Management, LP60,000New0.29%$2 MNov 16, 2026
44Bank Of America Corp /de/51,171+40,047 (+360.01%)0.25%$1 MNov 16, 2026
45Charles Schwab Investment Management Inc49,589+16,847 (+51.45%)0.24%$1 MNov 16, 2026
46ADAR1 Capital Management, LLC43,800+36,000 (+461.54%)0.21%$1 MNov 16, 2026
47Trexquant Investment LP43,503-30,259 (-41.02%)0.21%$1 MNov 16, 2026
48Wellington Management Group LLP40,732+9,339 (+29.75%)0.20%$1 MNov 16, 2026
49Bank of New York Mellon Corp38,710+9,969 (+34.69%)0.19%$1 MNov 5, 2026
50Nuveen, LLC35,994+8,170 (+29.36%)0.17%$1 MNov 10, 2026
51Raiffeisen Bank International AG34,0000 (0.00%)0.16%$1 MOct 28, 2026
52American Century Companies Inc30,063+6,733 (+28.86%)0.15%$1 MNov 12, 2026
53Quadrature Capital Ltd27,147+2,827 (+11.62%)0.13%$1 MNov 13, 2026
54Alps Advisors Inc26,528+10,488 (+65.39%)0.13%$1 MNov 3, 2026
55Millennium Management LLC24,633-18,101 (-42.36%)0.12%$1 MNov 16, 2026
56Informed Momentum Co LLC20,426New0.10%$1 MNov 16, 2026
57TD Asset Management Inc20,028New0.10%$1 MNov 13, 2026
58Rhumbline Advisers18,074+3,921 (+27.70%)0.09%$1 MNov 10, 2026
59SEI Investments Co16,758New0.08%$0 MNov 10, 2026
60Engineers Gate Manager LP15,380New0.07%$0 MNov 16, 2026
61Quantinno Capital Management LP15,196New0.07%$0 MNov 13, 2026
62AQR Capital Management LLC15,185+124 (+0.82%)0.07%$0 MNov 16, 2026
63Creative Planning14,933+4,352 (+41.13%)0.07%$0 MNov 2, 2026
64Seven Fleet Capital Management LP14,700-7,360 (-33.36%)0.07%$0 MNov 16, 2026
65Magnetar Financial LLC13,816New0.07%$0 MNov 13, 2026
66Price T Rowe Associates Inc /MD/12,980+4,084 (+45.91%)0.06%$0 MNov 16, 2026
67Bridgeway Capital Management, LLC12,551-6,230 (-33.17%)0.06%$0 MNov 16, 2026
68Empowered Funds, LLC12,551New0.06%$0 MNov 13, 2026
69Rafferty Asset Management, LLC11,591New0.06%$0 MNov 13, 2026
70Universal- Beteiligungs- und Servicegesellschaft mbH11,047New0.05%$0 MNov 10, 2026
71Virtus Investment Advisers, LLC10,905-339 (-3.01%)0.05%$0 MNov 12, 2026
72Alliancebernstein L.P.10,570-3,200 (-23.24%)0.05%$0 MNov 16, 2026
73Corient Private Wealth LP10,517New0.05%$0 MNov 16, 2026
74Renaissance Technologies LLC10,205-10,200 (-49.99%)0.05%$0 MNov 12, 2026
75Susquehanna International Group, LLP9,887New0.05%$0 MNov 16, 2026
76Vanguard Global Advisers, LLC9,642+4,788 (+98.64%)0.05%$0 MNov 13, 2026
77Citigroup Inc9,629+1,761 (+22.38%)0.05%$0 MNov 4, 2026
78Susquehanna Portfolio Strategies, LLC9,514New0.05%$0 MNov 16, 2026
79Barclays PLC9,427+6,117 (+184.80%)0.05%$0 MNov 6, 2026
80MetLife Investment Management, LLC8,986+3,054 (+51.48%)0.04%$0 MNov 16, 2026
81MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.8,420+3,213 (+61.71%)0.04%$0 MNov 16, 2026
82Keybank National Association/oh7,947New0.04%$0 MNov 4, 2026
83State Board Of Administration Of Florida Retirement System7,4910 (0.00%)0.04%$0 MNov 13, 2026
84XTX Topco Ltd7,465-47,959 (-86.53%)0.04%$0 MNov 16, 2026
85New York State Common Retirement Fund7,400+3,200 (+76.19%)0.04%$0 MNov 17, 2026
86Russell Investments Group, Ltd.6,358+368 (+6.14%)0.03%$0 MNov 6, 2026
87Mitsubishi UFJ Asset Management Co., Ltd.6,040-50 (-0.82%)0.03%$0 MNov 5, 2026
88BNP Paribas Financial Markets4,431+2,533 (+133.46%)0.02%$0 MNov 12, 2026
89Police & Firemen's Retirement System of New Jersey4,093+247 (+6.42%)0.02%$0 MNov 9, 2026
90China Universal Asset Management Co., Ltd.3,651+1,136 (+45.17%)0.02%$0 MOct 28, 2026
91Acadian Asset Management LLC3,172New0.02%$0 MNov 9, 2026
92Tower Research Capital LLC (TRC)3,112+2,672 (+607.27%)0.01%$0 MNov 16, 2026
93Royal Bank Of Canada3,074+668 (+27.76%)0.01%$0 MNov 16, 2026
94Wells Fargo & Company/mn3,056-6,415 (-67.73%)0.01%$0 MNov 16, 2026
95UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC3,055+2,763 (+946.23%)0.01%$0 MNov 16, 2026
96Legal & General Group Plc1,469+371 (+33.79%)0.01%$0 MNov 16, 2026
97Jones Financial Companies Lllp1,438New0.01%$0 MNov 13, 2026
98Ameritas Investment Partners, Inc.1,401+392 (+38.85%)0.01%$0 MNov 13, 2026
99Simplex Trading, LLC1,190New0.01%$0 MNov 4, 2026
100Mirae Asset Global Investments Co., Ltd.1,023+316 (+44.70%)0.00%$0 MOct 29, 2026

All 132 institutional investors, with who bought and sold →

Mutual funds holding Neurogene Inc.#

107 funds hold shares worth $75 M (about 11.5% of the company). Since their previous reports 54 added shares and 20 sold, buying $8 M net.
Mutual funds holding Neurogene Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.397,791$13 M1.9%<0.01%+4.1%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors296,322$9 M1.4%0.01%+9.6%Jun 30, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.218,783$7 M1.1%0.62%newJul 31, 2026
🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC177,200$6 M0.86%0.26%−27%Jul 31, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC124,026$4 M0.60%0.01%+11%Jul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.126,728$4 M0.61%<0.01%+5.1%Jun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors105,167$3 M0.51%0.02%+9.1%Jun 30, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC90,867$3 M0.44%0.05%+17%Jun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors88,398$3 M0.43%0.03%−6.6%Jun 30, 2026
🇺🇸 Meridian Small Cap Growth FundArrowMark Colorado Holdings, LLC75,859$2 M0.37%0.87%no changeJun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.57,993$2 M0.28%<0.01%+20%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC55,794$2 M0.27%<0.01%−1.9%May 31, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC51,100$1 M0.25%0.03%no changeMay 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors37,552$1 M0.18%0.08%+32%Jun 30, 2026
🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC36,199$1 M0.17%0.11%no changeJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.27,503$1 M0.13%0.01%+11%Jul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC20,627$1 M0.10%0.01%+23%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC18,781$1 M0.09%0.40%no changeJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust20,446$1 M0.10%0.02%+24%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC18,774$1 M0.09%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC15,827$0 M0.08%0.02%+13%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC15,005$0 M0.07%0.01%+21%Jul 31, 2026
🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc.15,498$0 M0.07%0.04%−6.7%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC16,206$0 M0.08%<0.01%+5.7%May 31, 2026
🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc.15,968$0 M0.08%0.28%+16%May 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP12,679$0 M0.06%<0.01%+51%Jul 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP12,271$0 M0.06%<0.01%+1602%Jul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC11,896$0 M0.06%<0.01%no changeJun 30, 2026
🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc.9,770$0 M0.05%0.02%−5.8%Jun 30, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.9,344$0 M0.05%0.03%newJul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC10,287$0 M0.05%<0.01%+31%May 31, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC8,852$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC8,240$0 M0.04%0.01%+24%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.8,684$0 M0.04%0.02%+21%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation7,100$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.6,409$0 M0.03%<0.01%−12%Jun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC5,853$0 M0.03%<0.01%+4.6%Jul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.5,675$0 M0.03%0.01%−3.1%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.5,645$0 M0.03%<0.01%+19%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC5,395$0 M0.03%0.01%+11%Jul 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.5,239$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC4,657$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC4,530$0 M0.02%<0.01%+55%Jun 30, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP4,300$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors4,401$0 M0.02%<0.01%−0.8%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC4,065$0 M0.02%<0.01%+4.1%Jul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP3,984$0 M0.02%<0.01%+93%Jul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.3,800$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Nationwide Bailard Small Cap Value FundNATIONWIDE FUND ADVISORS3,625$0 M0.02%0.09%no changeJul 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company4,187$0 M0.02%<0.01%+5.4%May 31, 2026
🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation3,459$0 M0.02%0.05%−5.3%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC3,411$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC3,321$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC3,044$0 M0.01%0.01%no changeJun 30, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP2,687$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC2,787$0 M0.01%0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC2,530$0 M0.01%0.04%+26%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS2,444$0 M0.01%0.01%no changeJun 30, 2026
🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC2,403$0 M0.01%0.02%−14%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC2,356$0 M0.01%0.01%+13%Jun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.2,329$0 M0.01%0.02%−4.5%Jun 30, 2026
🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC2,276$0 M0.01%0.02%−5.0%Jun 30, 2026
🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.1,907$0 M<0.01%0.03%newJun 30, 2026
🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company1,990$0 M<0.01%0.02%newMay 31, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC1,710$0 M<0.01%0.01%+5.2%Jul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.1,776$0 M<0.01%0.01%+12%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC1,645$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.1,706$0 M<0.01%0.01%+56%Jun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC1,663$0 M<0.01%0.01%no changeJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.1,626$0 M<0.01%<0.01%−31%Jun 30, 2026
🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP1,506$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION1,700$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC1,520$0 M<0.01%0.01%+21%Jun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.1,449$0 M<0.01%<0.01%+3.0%Jul 31, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP1,381$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Siit Small Cap II FundSEI INVESTMENTS MANAGEMENT CORPORATION1,558$0 M<0.01%0.02%no changeMay 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC1,290$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Siit Small Cap FundSEI INVESTMENTS MANAGEMENT CORPORATION1,400$0 M<0.01%0.02%no changeMay 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC1,186$0 M<0.01%0.01%+1.9%Jul 31, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC1,070$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS1,023$0 M<0.01%0.01%no changeJul 31, 2026
🇺🇸 SIMT Small Cap FundSEI Institutional Managed Trust1,060$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management1,009$0 M<0.01%0.01%no changeJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC938$0 M<0.01%0.02%no changeJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust1,009$0 M<0.01%0.02%no changeMay 31, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP796$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC815$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC809$0 M<0.01%0.01%+11%Jun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC776$0 M<0.01%<0.01%+10%Jun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC716$0 M<0.01%<0.01%+83%Jul 31, 2026
🇺🇸 SA Multi-Managed Small Cap PortfolioSunAmerica Asset Management, LLC730$0 M<0.01%0.02%−9.1%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.722$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC571$0 M<0.01%<0.01%+17%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC531$0 M<0.01%<0.01%+24%May 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC477$0 M<0.01%<0.01%−41%Jun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC445$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP400$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC400$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC420$0 M<0.01%<0.01%−31%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC416$0 M<0.01%<0.01%−32%May 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Neurogene Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$1.1 M
17 sales, 4 insiders
Net, 12 months
-$1.1 M
open market only
Insiders on file
28
since
$2.7 M-$373 K$0Nov 2024: bought $2.7 M (6 trades), sold $0 (0 trades)Nov 24Mar 2025: bought $0 (0 trades), sold $76 K (1 trades)MarMay 2025: bought $0 (0 trades), sold $103 K (1 trades)MayFeb 2026: bought $0 (0 trades), sold $121 K (1 trades)FebMar 2026: bought $0 (0 trades), sold $373 K (9 trades)MarMay 2026: bought $0 (0 trades), sold $300 K (2 trades)MayJul 2026: bought $0 (0 trades), sold $340 K (5 trades)Jul
Bought (open market)Sold (open market)Hover a month for the totals
Neurogene Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Rachel McMinnChief Executive Officer, DirectorOption exercise+756$25.32$19 K1.35 MForm 4
filed Christine Mikail CvijicPresident and CFO, DirectorSell10b5-1 plan-4,200$36.13$152 K84,040Form 4
filed Christine Mikail CvijicPresident and CFO, DirectorSell10b5-1 plan-600$36.02$22 K88,240Form 4
filed Christine Mikail CvijicPresident and CFO, DirectorSell10b5-1 plan-2,531$34.58$88 K90,370Form 4
filed Christine Mikail CvijicPresident and CFO, DirectorSell10b5-1 plan-1,530$35.23$54 K88,840Form 4
filed Christine Mikail CvijicPresident and CFO, DirectorSell10b5-1 plan-739$34.06$25 K92,901Form 4
filed Christine Mikail CvijicPresident and CFO, DirectorSell10b5-1 plan-4,800$30.07$144 K98,440Form 4
filed Christine Mikail CvijicPresident and CFO, DirectorSell10b5-1 plan-4,800$32.44$156 K93,640Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Neurogene Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
5.7 M
36.7% of shares · 16.95 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-4 reverse split ; 1-for-5 reverse split ; 1-for-19.19 reverse split in the period to ; 1-for-19.2 reverse split

Fails to deliver

  • : 6 shares at $28.82
  • : 11,639 shares at $30.42
  • : 6 shares at $26.99
  • : 88 shares at $21.56
  • : 20 shares at $24.44

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Neurogene Inc. scorecard#

Passes 1 of the 8 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-4.24 vs -4.28Diluted EPS -4.24 in fiscal 2025 against -4.28 the year before (report's currency).
    • ✗Net income higher than five years earlier-$90 M-$90 M in fiscal 2025 against -$33 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$90 MNet income -$90 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-31.4%-31.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities16.6×Current ratio 16.56 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year21.4%Diluted shares up 21.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Neurogene Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Neurogene Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue00.90————25——
Research and development75614448r39244.4423628
General and administrative2823119.0r22171916159.3
Operating expenses103845657r61—71585138
Operating income−103−83−56−57r−61−34−71−33−51−38
Interest and finance income128.53.01.3——————
Interest expense and finance costs0.00.00.00.0——0.00.00.00.0
Net interest income———1.60.0—————
Other non-operating income (expense)137.5—−0.0−0.0r0.51.51.00.90.6
Income before tax−90−75−36−55r−61−33−69−32−50−37
Income tax00———————0
Net income including minority interests——————−69−32−50−37
Net income attributable to shareholders−90−75−36−55r−61−33−69−32−50−37
Earnings per share, basic-4.24-4.28—-1.04-1.10-0.64-2.57-1.34-2.14-1.96
Earnings per share, diluted-4.24-4.28—-1.04-1.10-0.64-2.57-1.34-2.14-1.96
Shares, weighted average (basic)2118—555552————
Shares, weighted average (diluted)2118—55555227242319
Balance sheet
Cash and cash equivalents10413714882r142193143775232
Short-term investments165176490r0—————
Other current assets0.21.01.10.6r1.52.00.5———
Current assets27231620085r14419514477109103
Property, plant and equipment13151720r6.53.62.10.40.90.8
Right-of-use (leased) assets2.63.03.74.3r11100.8———
Other intangible assets———00.10.30.6———
Total assets289336223109r16321114778110154
Accounts payable2.01.32.60.6r0.5r1.3r1.6r0.76.06.9
Current liabilities1615236.7r8.67.94.74.6119.5
Lease liabilities (non-current)6.89.4123.9r12110.4———
Total liabilities24253711r20195.34.9119.7
Retained earnings−353−262−187−151r−393−333−300−230−199−148
Shareholders' equity265310186−146r−92r1911427399145
Total liabilities and equity289336223109r16321114778110154
Shares outstanding151513—424238242323
Cash-flow statement
Depreciation and amortization3.03.23.33.2r1.30.80.30.30.4—
Share-based compensation148.31.41.3r125.67.74.73.82.0
Cash from operating activities−77−71−51−53r−48−25−15−32−45−30
Capital expenditure−1.2−0.8−0.3−2.2r−3.3−2.2−0.9−0.0−0.5−0.7
Cash from investing activities14−12526−2.2r−3.3−2.2−0.75664−48
Shares issued30092007281r——75
Cash from financing activities301849267r0.777820.60.471
Exchange-rate effect on cash—————00.0−0.00.0−0.1
Change in cash−33−126711r−5050662520−7.2
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Neurogene Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$3.2 M
Other top executives, average
$2.1 M
the CEO earned 1.5× this
$100 invested is now
$202
Neurogene Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chief executive$3.2 M$3.2 M$2.1 M$202
2024Chief executive$3.5 M$2.7 M$2.9 M$225
2023Chief executive$1.8 M$1.9 M$1.2 M$190

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Neurogene Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 3 · Unregistered share sale 1 · Shareholder vote 2 · Results announced 9

Neurogene Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Material agreement8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

5 private funding rounds before listing

Private share sales · funding history

Private share sales of Neurogene Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2013$14 MNo. 5$10 to $50 million7equity, optionsSEC
Sep 2011$4 MNo. 4$2 to $10 million6equity, optionsSEC
Jan 2011$5 MNo. 3$2 to $10 million6equity, optionsSEC
Jun 2010$4 MNo. 2$2 to $10 million1equity, optionsSEC
Mar 2010$5 MNo. 1$2 to $10 million5equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Neurogene Inc.#

1 labor condition applications certified in fiscal 2020 for 1 positions, at a median wage of $110 K a year.

Certified, FY2020
1
#1,927 among companies on value.today
Worker positions
1
Median wage offered
$110 K
a year, full-time
Applications filed
1
Neurogene Inc.: most frequent H-1B job titles in fiscal 2020
Job titlePositionsMedian wage offered
Senior Production Planner/SchedulerLogisticians1$110 K

Where: Houston, TX 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Neurogene Inc.

Layoffs at Neurogene Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
30
2018–2023
Latest
—
2023-03-06
Neurogene Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2023············—
2018······30·····30
Neurogene Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
70% of workforceRestructuring planSEC 8-K“(the "Company") approved a reduction in force of the Company's workforce by approximately 70% and a re-prioritization of the Company’s focus to seek strategic alternatives to maxim…”Filing
30 peopleRestructuring planSEC 8-K“Under this plan, the Company reduced its workforce by 30 employees (approximately 53%) and closed its office in San Bruno, California.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Neurogene Inc. compares in Pharmaceutical

  • Revenue$0 M · higher than 0% of 324

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Neurogene Inc.🇺🇸$30 M———
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jul 30, 2023 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 16, 2026
Profile updated:
Nov 16, 2026

Figures from value.today research.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Neurogene Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Neurogene Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Neurogene Inc.? Suggest a correction